Acadia Pharmaceuticals Inc (ACAD)
- Sector
- Biotechnology
- Last price
- $21.23
- As of
Kresmion compiles this page from ACAD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ACADIA PHARMACEUTICALS INC (ACAD): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full ACAD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ACAD on one page. Preview it with sample data, then open it live with a free account.
Preview the ACAD dossierActive events for ACAD
- high13F: funds added
3 tracked funds increased ACAD this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 207.2%, EPS $0.18 vs $0.0586 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +212% to ACAD (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +8293% to ACAD (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +17660% to ACAD (2026Q2)
FREE, NO ACCOUNT
Every event on ACAD, as it fires
You are seeing 5 of 13 events recorded on ACAD since 2026-05-16.
The five above landed across 3 days. The other 8 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ACAD positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| Point72 Asset Management, L.P. FundCUSIP 004225108 · 2026Q2 | $61.6M | 0.09% |
| CITADEL ADVISORS LLC FundCUSIP 004225108 · 2026Q2 | $55.2M | 0.03% |
| D. E. Shaw & Co., Inc. FundCUSIP 004225108 · 2026Q2 | $43M | 0.03% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 004225108 · 2026Q2 | $32.4M | 0.04% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 004225108 · 2026Q2 | $23.5M | 0.02% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 004225108 · 2026Q2 | $14.9M | 0.01% |
| Bridgewater Associates, LP FundCUSIP 004225108 · 2026Q2 | $1.3M | 0.01% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACAD
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on ACAD
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ACAD on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ACAD in the last 180 days.
Upstream: SEC EDGAR filings for ACAD
Kresmion, "ACADIA PHARMACEUTICALS INC (ACAD) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/ACAD. Upstream data: SEC EDGAR filings for ACAD.
Link to this data (HTML):
<a href="https://kresmion.com/research/ACAD">ACADIA PHARMACEUTICALS INC (ACAD) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ACAD on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ACAD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.